|
1
|
Shih KK and Chi DS: Maximal cytoreductive
effort in epithelial ovarian cancer surgery. J Gynecol Oncol.
21:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dalton SO, Mellemkjaer L, Thomassen L,
Mortensen PB and Johansen C: Risk for cancer in a cohort of
patients hospitalized for schizophrenia in Denmark, 1969–1993.
Schizophr Res. 75:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mortensen PB: The incidence of cancer in
schizophrenic patients. J Epidemiol Community Health. 43:43–47.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Driver JA, Logroscino G, Buring JE,
Gaziano JM and Kurth T: A prospective cohort study of cancer
incidence following the diagnosis of Parkinson's disease. Cancer
Epidemiol Biomarkers Prev. 16:1260–1265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kilts CD, Knight DL, Mailman RB, Widerlöv
E and Breese GR: Effects of thioridazine and its metabolites on
dopaminergic function: Drug metabolism as a determinant of the
antidopaminergic actions of thioridazine. J Pharmacol Exp Ther.
231:334–342. 1984.PubMed/NCBI
|
|
7
|
Yin T, He S, Shen G, Ye T, Guo F and Wang
Y: Dopamine receptor antagonist thioridazine inhibits tumor growth
in a murine breast cancer model. Mol Med Rep. 12:4103–4108. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K,
Shi Y, Zhang C, Chen H and Li Z: Roles of dopamine receptors and
their antagonist thioridazine in hepatoma metastasis. OncoTargets
Ther. 8:1543–1552. 2015.
|
|
9
|
Mao M, Yu T, Hu J and Hu L: Dopamine D2
receptor blocker thioridazine induces cell death in human uterine
cervical carcinoma cell line SiHa. J Obstet Gynaecol Res.
41:1240–1245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS,
He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, et
al: Biologic effects of dopamine on tumor vasculature in ovarian
carcinoma. Neoplasia. 15:502–510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olive PL and Banáth JP: The comet assay: A
method to measure DNA damage in individual cells. Nat Protoc.
1:23–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pozzi L, Håkansson K, Usiello A, Borgkvist
A, Lindskog M, Greengard P and Fisone G: Opposite regulation by
typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1
phosphorylation in mouse dorsal striatum. J Neurochem. 86:451–459.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rodrigues-Ferreira S and Nahmias C:
G-protein coupled receptors of the renin-angiotensin system: New
targets against breast cancer? Front Pharmacol. 6:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berhow MT, Hiroi N and Nestler EJ:
Regulation of ERK (extracellular signal regulated kinase), part of
the neurotrophin signal transduction cascade, in the rat mesolimbic
dopamine system by chronic exposure to morphine or cocaine. J
Neurosci. 16:4707–4715. 1996.PubMed/NCBI
|
|
15
|
Nahata MC, Ford C and Ruymann FB:
Pharmacokinetics and safety of prochlorperazine in paediatric
patients receiving cancer chemotherapy. J Clin Pharm Ther.
17:121–123. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morgan RJ Jr, Synold T, Carr BI, Doroshow
JH, Womack EP, Shibata S, Somlo G, Raschko J, Leong L, McNamara M,
et al: Continuous infusion prochlorperazine: Pharmacokinetics,
antiemetic efficacy, and feasibility of high-dose therapy. Cancer
Chemother Pharmacol. 47:327–332. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adams JM: Ways of dying: Multiple pathways
to apoptosis. Genes Dev. 17:2481–2495. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu HM, Jiang ZF, Ding PS, Shao LJ and Liu
RY: Hypoxia-induced autophagy mediates cisplatin resistance in lung
cancer cells. Sci Rep. 5:122912015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
García-Cano J, Ambroise G, Pascual-Serra
R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater
S, Ruiz-Hidalgo MJ, Sanchez Perez I, et al: Exploiting the
potential of autophagy in cisplatin therapy: A new strategy to
overcome resistance. Oncotarget. 6:15551–15565. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin
CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, et al:
Identification of thioridazine, an antipsychotic drug, as an
antiglioblastoma and anticancer stem cell agent using public gene
expression data. Cell Death Dis. 6:e17532015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin S and White E: Role of autophagy in
cancer: Management of metabolic stress. Autophagy. 3:28–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boya P, González-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daido S, Kanzawa T, Yamamoto A, Takeuchi
H, Kondo Y and Kondo S: Pivotal role of the cell death factor BNIP3
in ceramide-induced autophagic cell death in malignant glioma
cells. Cancer Res. 64:4286–4293. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanzawa T, Kondo Y, Ito H, Kondo S and
Germano I: Induction of autophagic cell death in malignant glioma
cells by arsenic trioxide. Cancer Res. 63:2103–2108.
2003.PubMed/NCBI
|
|
25
|
Paglin S, Hollister T, Delohery T, Hackett
N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response
of cancer cells to radiation involves autophagy and formation of
acidic vesicles. Cancer Res. 61:439–444. 2001.PubMed/NCBI
|
|
26
|
Yu L, Alva A, Su H, Dutt P, Freundt E,
Welsh S, Baehrecke EH and Lenardo MJ: Regulation of an ATG7-beclin
1 program of autophagic cell death by caspase-8. Science.
304:1500–1502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang Y, Cong H, Han C, Yue L, Dong H and
Liu J: 12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF
and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling
pathway. Oncol Rep. 34:1755–1760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ioannou M, Paraskeva E, Baxevanidou K,
Simos G, Papamichali R, Papacharalambous C, Samara M and Koukoulis
G: HIF-1alpha in colorectal carcinoma: Review of the literature. J
BUON. 20:680–689. 2015.PubMed/NCBI
|
|
29
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park MS, Dong SM, Kim BR, Seo SH, Kang S,
Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and
tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian
cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX,
Yao M, Zhang DD and Yi XF: Nrf2 induces cisplatin resistance
through activation of autophagy in ovarian carcinoma. Int J Clin
Exp Pathol. 7:1502–1513. 2014.PubMed/NCBI
|
|
32
|
Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick
JL and Yang YY: Co-delivery of thioridazine and doxorubicin using
polymeric micelles for targeting both cancer cells and cancer stem
cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gabalec F, Beranek M, Netuka D, Masopust
V, Nahlovsky J, Cesak T, Marek J and Cap J: Dopamine 2 receptor
expression in various pathological types of clinically
non-functioning pituitary adenomas. Pituitary. 15:222–226. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gatto F and Hofland LJ: The role of
somatostatin and dopamine D2 receptors in endocrine tumors. Endocr
Relat Cancer. 18:R233–R251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gil-Ad I, Shtaif B, Levkovitz Y,
Nordenberg J, Taler M, Korov I and Weizman A: Phenothiazines induce
apoptosis in a B16 mouse melanoma cell line and attenuate in vivo
melanoma tumor growth. Oncol Rep. 15:107–112. 2006.PubMed/NCBI
|
|
36
|
Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei
N, Sun LY, Cao X, Li HG, Zhang KJ, et al: HCCS1-armed,
quadruple-regulated oncolytic adenovirus specific for liver cancer
as a cancer targeting gene-viro-therapy strategy. Mol Cancer.
10:1332011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sheikhpour M, Ahangari G, Sadeghizadeh M
and Deezagi A: A novel report of apoptosis in human lung carcinoma
cells using selective agonist of D2-like dopamine receptors: A new
approach for the treatment of human non-small cell lung cancer. Int
J Immunopathol Pharmacol. 26:393–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
